Eliem Therapeutics (ELYM) Insider Trading & Ownership $1.81 -0.17 (-8.59%) As of 10/6/2025 Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Eliem Therapeutics (NASDAQ:ELYM) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.70%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$49.95MNumber OfInsiders Selling(Last 3 Years)2Amount OfInsider Selling(Last 3 Years)$2.15M Get ELYM Insider Trade Alerts Want to know when executives and insiders are buying or selling Eliem Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELYM Insider Buying and Selling by Quarter Eliem Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/20/2024Emily PimblettCAOSell1,191$8.18$9,742.38 7/22/2024Valerie MorissetEVPSell69,005$8.03$554,110.15 7/19/2024Valerie MorissetEVPSell60,201$7.21$434,049.21 7/17/2024Valerie MorissetEVPSell3,207$6.91$22,160.37 7/15/2024Valerie MorissetEVPSell42,377$7.01$297,062.77 7/11/2024Valerie MorissetEVPSell50,000$7.11$355,500.00 7/9/2024Valerie MorissetEVPSell5,931$6.66$39,500.46 7/5/2024Valerie MorissetEVPSell12,342$7.06$87,134.52 7/3/2024Valerie MorissetEVPSell50,000$6.76$338,000.00 6/27/2024Ra Capital Management, L.P.DirectorBuy13,008,546$3.84$49,952,816.64 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 6/20/2024Emily PimblettCAOSell1,245$7.21$8,976.45 (Data available from 1/1/2013 forward) ELYM Insider Trading Activity - Frequently Asked Questions Who is on Eliem Therapeutics' Insider Roster? The list of insiders at Eliem Therapeutics includes Emily Pimblett, Ra Capital Management, L.P., and Valerie Morisset. Learn more on insiders at ELYM. What percentage of Eliem Therapeutics stock is owned by insiders? 4.70% of Eliem Therapeutics stock is owned by insiders. Learn more on ELYM's insider holdings. Which Eliem Therapeutics insiders have been buying company stock? The following insider purchased ELYM shares in the last 24 months: Ra Capital Management, L.P. ($49,952,816.64). How much insider buying is happening at Eliem Therapeutics? Insiders have purchased a total of 13,008,546 ELYM shares in the last 24 months for a total of $49,952,816.64 bought. Which Eliem Therapeutics insiders have been selling company stock? The following insiders have sold ELYM shares in the last 24 months: Emily Pimblett ($18,718.83), and Valerie Morisset ($2,127,517.48). How much insider selling is happening at Eliem Therapeutics? Insiders have sold a total of 295,499 Eliem Therapeutics shares in the last 24 months for a total of $2,146,236.31 sold. Eliem Therapeutics Key ExecutivesDr. Andrew Levin M.D. (Age 46)Ph.D., Principal Financial Officer & Executive Chairman Compensation: $73kDr. Valerie Morisset Ph.D. (Age 54)Chief Scientific Officer and Executive VP of Research & Development Compensation: $617.87kMs. Emily Pimblett (Age 40)Principal Accounting Officer Ms. Jo Palmer-Phillips Ph.D.Chief Development Officer More Insider Trading Tools from MarketBeat Related Companies Heron Therapeutics Insider Selling Atea Pharmaceuticals Insider Selling Sagimet Biosciences Insider Selling Ventyx Biosciences Insider Selling Entrada Therapeutics Insider Selling Caribou Biosciences Insider Selling Black Diamond Therapeutics Insider Selling Cabaletta Bio Insider Selling Tonix Pharmaceuticals Insider Selling Aclaris Therapeutics Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Marvell Insiders Buy Shares—Should Investors Follow Suit?This Insider Just Made a Massive Bet on Transocean's ComebackInsider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t WorryTop Insider Buys and Sells From September: Buy, Sell, or Hold? This page (NASDAQ:ELYM) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredThe 'Big Beautiful Bill' That Could Break AmericaOn July 4th, they celebrated the $3.4 trillion "One Big Beautiful Bill Act." What they didn't say? This bil...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
